Search research articles
Contact Us
Filters
Showing results (61-70 of 519) with videos related to
Page
of 52
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2020
Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma
Francesco Maura, Ola Landgren, Gareth J Morgan
Journal of the National Cancer Institute
|
August 19, 2009
Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials
Ola Landgren, Kieron Dunleavy, Wyndham H Wilson
Blood
|
March 29, 2011
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
Neha Korde, Sigurdur Y Kristinsson, Ola Landgren
Blood Cancer Journal
|
September 8, 2018
Biological determinants of health disparities in multiple myeloma
Cheryl Jacobs Smith, Stefan Ambs, Ola Landgren
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 30, 2025
CD38-Targeted <sup>89</sup>Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care
Gary A Ulaner, Jason Lewis, Ola Landgren
Clinical Lymphoma, Myeloma & Leukemia
|
March 16, 2013
Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia
Sigurdur Y Kristinsson, Magnus Björkholm, Ola Landgren
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 21, 2015
Multiple myeloma: is it time for biomarker-driven therapy?
Manisha Bhutani, Ola Landgren, Saad Z Usmani
Seminars in Hematology
|
May 16, 2018
MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
Ola Landgren, Sydney X Lu, Malin Hultcrantz
Blood
|
August 10, 2013
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
Aaron Flanders, Maryalice Stetler-Stevenson, Ola Landgren
Leukemia Research Reports
|
July 25, 2020
Management of multiple myeloma during COVID-19 pandemic
Y S Jethava, Rafael Fonseca, Ola Landgren
Page
of 52
Search research articles
Search
Showing results (61-70 of 519) with videos related to
Sort By:
Page
of 52
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2020
Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma
Francesco Maura, Ola Landgren, Gareth J Morgan
Journal of the National Cancer Institute
|
August 19, 2009
Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials
Ola Landgren, Kieron Dunleavy, Wyndham H Wilson
Blood
|
March 29, 2011
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
Neha Korde, Sigurdur Y Kristinsson, Ola Landgren
Blood Cancer Journal
|
September 8, 2018
Biological determinants of health disparities in multiple myeloma
Cheryl Jacobs Smith, Stefan Ambs, Ola Landgren
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 30, 2025
CD38-Targeted <sup>89</sup>Zr-DFO-Daratumumab PET of Myeloma: Immuno-PET Impacting Clinical Care
Gary A Ulaner, Jason Lewis, Ola Landgren
Clinical Lymphoma, Myeloma & Leukemia
|
March 16, 2013
Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia
Sigurdur Y Kristinsson, Magnus Björkholm, Ola Landgren
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 21, 2015
Multiple myeloma: is it time for biomarker-driven therapy?
Manisha Bhutani, Ola Landgren, Saad Z Usmani
Seminars in Hematology
|
May 16, 2018
MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
Ola Landgren, Sydney X Lu, Malin Hultcrantz
Blood
|
August 10, 2013
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
Aaron Flanders, Maryalice Stetler-Stevenson, Ola Landgren
Leukemia Research Reports
|
July 25, 2020
Management of multiple myeloma during COVID-19 pandemic
Y S Jethava, Rafael Fonseca, Ola Landgren
Page
of 52